In order to investigate whether the levels of LGMN, C1Q (upregulated in CPZ) and HEMO (upregulated in EAE16d) were significantly affected in CSF samples from multiple sclerosis patients (Table 2), a targeted LC–MS/MS PRM assay for quantification was developed. This evidence concerns the gene LGMN and multiple sclerosis.